Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease

Table 1 Baseline characteristics of the 40 patients with Crohn’s disease included in this study

	n = 40 patients
Age at the time of inclusion, mean ± SD (yr)	34 .0 ± 13.6
Disease duration, median (IQR) (yr)	4 (0.8-11.3)
Female gender, n (%)	21 (52.5)
Current smokers, n (%)	15 (37.5)
Prior bowel resection, n (%)	7 (17.5)
Montreal classification
Location
L1, n (%)	18 (45.0)
L2, n (%)	3 (7.5)
L3, n (%)	19 (47.5)
Behaviour
B1, n (%)	13 (32.5)
B2, n (%)	16 (40.0)
B3, n (%)	11 (27.5)
Perianal lesions, n (%)	7 (17.5)
Anti-TNF-naïve patients, n (%)	24 (60.0)
Type of anti-TNF
Infliximab, n (%)	16 (40.0)
Adalimumab, n (%)	24 (60.0)
Concomitant medications
Immunosuppressive therapies, n (%)	21 (52.5)
Steroids, n (%)	7 (17.5)
Faecal calprotectin level at baseline, median (IQR) (µg/g)	1010.5 (357.8-1800.0)
CRP level at baseline, median (IQR) (mg/L)	13.2 (5.2-25.9)

SD: Standard deviation; IQR: Interquartile range; TNF: Tumor necrosis factor.